- Home
- AFJK vs QNCX Comparison
AFJK vs QNCX Comparison
Compare AFJK & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFJK
- QNCX
- Stock Information
- Founded
- AFJK 2023
- QNCX 2012
- Country
- AFJK United States
- QNCX United States
- Employees
- AFJK N/A
- QNCX N/A
- Industry
- AFJK
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AFJK
- QNCX Health Care
- Exchange
- AFJK NYSE
- QNCX Nasdaq
- Market Cap
- AFJK 95.7M
- QNCX 92.3M
- IPO Year
- AFJK 2023
- QNCX 2019
- Fundamental
- Price
- AFJK $10.64
- QNCX $1.95
- Analyst Decision
- AFJK
- QNCX Strong Buy
- Analyst Count
- AFJK 0
- QNCX 3
- Target Price
- AFJK N/A
- QNCX $9.67
- AVG Volume (30 Days)
- AFJK 107.5K
- QNCX 286.7K
- Earning Date
- AFJK 01-01-0001
- QNCX 11-13-2024
- Dividend Yield
- AFJK N/A
- QNCX N/A
- EPS Growth
- AFJK N/A
- QNCX N/A
- EPS
- AFJK 0.29
- QNCX N/A
- Revenue
- AFJK N/A
- QNCX N/A
- Revenue This Year
- AFJK N/A
- QNCX N/A
- Revenue Next Year
- AFJK N/A
- QNCX N/A
- P/E Ratio
- AFJK $36.16
- QNCX N/A
- Revenue Growth
- AFJK N/A
- QNCX N/A
- 52 Week Low
- AFJK $10.15
- QNCX $0.51
- 52 Week High
- AFJK $10.69
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- AFJK N/A
- QNCX 52.02
- Support Level
- AFJK N/A
- QNCX $1.80
- Resistance Level
- AFJK N/A
- QNCX $2.09
- Average True Range (ATR)
- AFJK 0.00
- QNCX 0.21
- MACD
- AFJK 0.00
- QNCX -0.05
- Stochastic Oscillator
- AFJK 0.00
- QNCX 27.01
About AFJK AIMEI HEALTH TECHNOLOGY CO LTD
Aimei Health Technology Co Ltd is a blank check company.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.